Faron Pharmaceuticals Oy

FARN · AIM · Health Care · mcap £77m · 36.5p

Beta Briefing, track record and bull & bear case are not ready for Faron Pharmaceuticals Oy yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

Faron Pharmaceuticals Ltd 11 Jun – 4 Aug · 2 notices

below 3% → 9.4%

share price at the notices 42.0–43.5p · now 36.5p 11 Jun 2026 4 Aug 2026

Heights Capital Management, Inc. 20 Apr – 17 Sep · 11 notices

6.7% → 8.7%

share price at the notices 35.0–47.4p · now 36.5p 20 Apr 2026 22 Apr 2026 5 May 2026 1 Jun 2026 4 Jun 2026 15 Jun 2026 24 Jul 2026 5 Aug 2026 7 Sep 2026 17 Sep 2026

Timo Syrjälä 21 Oct – 17 Jun · 6 notices

below 3% → 6.5%

share price at the notices 42.5–182.5p · now 36.5p 21 Oct 2025 4 Dec 2025 12 Mar 2026 24 Mar 2026 16 Apr 2026 17 Jun 2026

Blood Cancer United, Inc. 18 May · 1 notice

below 3% → 3.5%

share price at the notices 43.5p · now 36.5p 18 May 2026

Pentwater Capital Management LP 8 Jun – 4 Sep · 2 notices

4.3% → 3.0%

share price at the notices 38.0–45.0p · now 36.5p 8 Jun 2026 4 Sep 2026

Varma Mutual Pension Insurance Company 11 Mar · 1 notice

4.2% → 2.2%

share price at the notices 47.0p · now 36.5p 11 Mar 2026

Bank of America Corporation 28 May – 17 Jun · 3 notices

0.1% → 0.1%

share price at the notices 42.5–47.0p · now 36.5p 28 May 2026 10 Jun 2026 17 Jun 2026

Directors

sale Faron Pharmaceuticals Ltd. announced that its Chief Financial Officer, Jurriaan Dekkers, sold 4,000 ordinary shares at £1.822 per share on January 12, 2026. This transaction resulted in Mr. Dekkers holding zero ordinary 13 Jan 2026

other Faron Pharmaceuticals Ltd. announced that Pacta sunt servanda Oy, wholly owned by the company's General Counsel, subscribed to 72,000 ordinary shares at EUR 0.5 per share on March 18, 2026, as part of a rights issue. Thi 19 Mar 2026

purchase Faron Pharmaceuticals Ltd. announced that Yrjö Wichmann, a Senior Advisor, acquired 10,000 ordinary shares on March 17, 2026, at a price of EUR 0.51942 per share. This transaction, totaling EUR 5,194.20, was conducted on 19 Mar 2026

purchase Faron Pharmaceuticals Ltd. announced that its CEO, Juho Jalkanen, subscribed to 23,656 ordinary shares at EUR 0.5 per share on March 17, 2026, as part of a rights issue. Additionally, Mr. Jalkanen acquired 4,860 ordinary 19 Mar 2026

other Faron Pharmaceuticals Ltd. announced that Sirpa Jalkanen, a scientific founder and closely associated person to a board member, subscribed to 100,008 ordinary shares at €0.5 per share on March 24, 2026, as part of the co 25 Mar 2026

other Faron Pharmaceuticals Ltd. announced that its Non-Executive Chairman, Tuomo Pätsi, subscribed for 400,002 ordinary shares at €0.5 per share on March 30, 2026, as part of the company's rights issue. This transaction repre 31 Mar 2026

award Faron Pharmaceuticals Ltd. has appointed Dr. George Stanley Golumbeski as a Non-executive Director, effective immediately, bringing extensive experience from his role at DROIA Ventures and previous leadership positions a 5 May 2026

Company filings. Not investment advice.